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Abstract
Background: HIV-positive patients are increasingly being affected by non-communicable diseases such as coronary
artery disease (CAD). Data from high-income countries (HICs) indicate that HIV-positive patients have different risk-
factor profiles for acute coronary syndrome (ACS) as well as different cardiac manifestations of this syndrome
compared to HIV-negative patients. There is limited data from Sub-Saharan Africa (SSA), and particularly from South
Africa with the biggest HIV epidemic in the world. The objective of this study was to determine the 12-month
period prevalence of HIV in patients with ACS and to compare the risk-factor profile, ACS presentation and
management between HIV-positive and HIV-negative adults.
Methods: We included all patients hospitalised with ACS from 01 January to 31 December 2018 in a tertiary
hospital, Tygerberg Hospital, in Cape Town, South Africa. The HIV-status of all patients was determined using
routine clinical records. We performed multiple conditional logistic regression on HIV-positive and HIV-negative
patients (1:3 ratio) to compare the risk factor profile, ACS presentation and management between the groups.
Results: Among 889 patients, 30 (3.4%) were HIV-positive (95% confidence interval (CI): 2.3–4.8). HIV-positive
patients were younger, more frequently men, and had a lower prevalence of medical comorbidities and a family
history of CAD. They were more likely to present with ST-elevation myocardial infarction (STEMI) [odd’s ratio (OR)
(95% CI): 3.12 (1.2–8.4)], and have single-vessel disease [OR (95% CI): 3.03 (1.2–8.0)]. Angiographic and
echocardiographic data, as well as management, did not differ between the groups. Among HIV-positive patients,
17 (65%) were virally suppressed (HIV viral load < 200 copies/mL) with a median CD4+ count of 271 cells/mm3. The
majority (20, 67%) of HIV-positive patients were receiving antiretroviral therapy at the time of the ACS.
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Conclusions: We found an HIV-prevalence of 3.4% (95% CI 2.3–4.8) in adults with ACS in a high endemic HIV
region. HIV-positive patients were younger and more likely to present with STEMIs and single-vessel disease, but
had fewer CAD risk factors, suggesting additional mechanisms for the development of ACS.
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Background
The incidence of acute coronary syndrome (ACS) in
HIV-positive individuals is increasing [1]. Antiretroviral
therapy (ART) treated HIV-positive patients are experi-
encing fewer HIV-related opportunistic infections and
are increasingly being affected by the same age-
associated spectrum of atherosclerotic disease, including
coronary artery disease (CAD), as the general population
[2]. Atherosclerotic disease, however, is emerging about
10 years earlier than in their uninfected counterparts,
suggesting an alternative pathogenesis in HIV-positive
patients [3]. CAD accounts for 8–22% of deaths among
the HIV-positive population, making it an important
cause of morbidity and mortality [4]. This is in contrast
to the pre-ART era, when cardiomyopathies, pancarditis,
conduction system abnormalities, pulmonary hyperten-
sion leading to heart failure, and neoplastic infiltration
were more important cardiac manifestations of HIV
infection [5].
Despite much data from Europe and North America,
there are limited studies from South Africa, a low and
middle-income country (LMIC), reporting on the preva-
lence of HIV in ACS, as well as the CAD risk factors,
cardiac manifestations and management of ACS in these
patients [6]. Most studies demonstrate HIV-positive pa-
tients with ACS to be younger, predominantly male,
likely to smoke but with a lower prevalence of traditional
CAD risk factors (diabetes mellitus, hypertension, dysli-
pidaemia) compared to their HIV-negative counterparts
[1]. The increased incidence of ACS in the HIV-positive
population suggests additional pathogenic mechanisms
including increased survival time, ongoing HIV inflam-
mation, immune-activation and ART-induced metabolic
derangements [4, 7]. Chronic HIV-associated inflamma-
tion is associated with abnormal lipid profiles independ-
ent of ART, unstable plaque morphology, and more
severe coronary artery stenosis [8]. Furthermore, it has
been shown that HIV-positive patients have increased
C-reactive protein, interleukin-6 and D-dimer levels,
contributing to a pro-inflammatory and pro-thrombotic
environment [5]. HIV-replication and immune-
activation causes up-regulation of tissue factor pathways
and chronic platelet activation, which may promote
atherogenesis and put these patients at an increased risk
of thrombotic events [7]. The clinical presentation of
HIV-positive patients with CAD seems to be similar to
that of the general population, and includes silent is-
chaemia, stable angina and ACS [7]. ACS is the main
clinical presentation, of which ST-segment elevation
myocardial infarction (STEMI) is the main sub-type.
Non-ST-elevated myocardial infarction (NSTEMI) and
unstable angina (UA) are the most common presenta-
tions of ACS in HIV-uninfected persons [1].
CAD is no longer a disease affecting just the high-
income countries (HICs); LMICs today are experiencing a
greater morbidity and mortality from ACS, with the death
toll affecting the younger, productive ages more heavily
[9]. This is evidenced by the shift from communicable dis-
eases (48.1% prevalence in 2005; 31.3% prevalence in
2016) to non-communicable diseases (42.9% prevalence in
2005; 57.4% prevalence in 2016) as the primary cause of
death in South Africans in the last decade [10]. Despite
this, HIV still affects 13.1% of the South African popula-
tion [11]. HIV-positive patients are hypothesised to be at
an increased risk for CAD and the combined effect of
these two distinct epidemics may have a marked impact
on morbidity and life expectancy [7, 12].
We conducted a retrospective cross-sectional study to
estimate the 12-month period prevalence of HIV in a
South African population from Cape Town presenting
with ACS. The second objective of the study aims to de-
scribe the CAD risk factors, cardiac manifestations, and
management of HIV-positive patients in comparison to
HIV-negative patients, using a case-control study design.
Methods
We conducted a retrospective review of all adult pa-
tients presenting to Tygerberg Hospital (TBH), Cape
Town, from 01 January to 31 December 2018 with
ACS. TBH is the largest public-sector tertiary referral
hospital in the Cape Town Metropole and serves over
3.4 million people; mostly vulnerable populations
from densely populated low-income communities and
rural areas.
Patients were identified using clopidogrel prescription
data from the JAC electronic dispensing system [13]. We
used the Electronic Content Management System
(ECM) to access stored medical records to identify pa-
tients with the diagnosis of ACS documented in their
medical record as the indication for clopidogrel treat-
ment. The diagnosis of myocardial infarction (MI) at
Tygerberg Hospital is made according to the Fourth
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Universal Definition: acute myocardial injury with clin-
ical evidence of acute myocardial ischaemia and a rise of
cardiac troponin levels with at least one value >99th per-
centile of the upper reference limit and at least one of
the following: symptoms of myocardial ischaemia, new
ischaemic changes on the ECG, pathological Q-waves on
the ECG, imaging evidence of new loss of myocardium
or new localised wall motion abnormality in a pattern
indicative of ischaemic causes, presence of a coronary
thrombus by angiography [14]. UA is diagnosed by the
presence of ischaemic symptoms suggestive of ACS,
without elevated biomarkers or ECG changes suggestive
of infarction [14]. The diagnosis of ACS was confirmed
by reviewing attending physician discharge summaries,
and cross-checking the admission records, electrocardio-
grams (ECGs), troponin levels, echocardiograms and
angiogram reports of each patient. Patients with re-
peated ACS-events within the year were only counted
once, and their first ACS-event within the year was
described.
We extracted the HIV status of all patients with a clin-
ical diagnosis of ACS to determine the period preva-
lence. HIV data was obtained from the South African
National Health Laboratory Service (NHLS) database.
The NHLS is the only service provider of HIV testing in
the public sector and an absent result implies that HIV
testing was not done in the public sector. HIV-positive
patients were classified as virally supressed (VL < 200
copies/mL) or virally unsuppressed (VL > 200 copies/
mL), and the number of immune-suppressed patients
(CD4+ count < 500 cells/mm3) was described.
In the case-control analysis of our study we compared
the CAD risk factors, ACS-type and management of
HIV-positive compared with HIV-negative patients with
ACS. In order to do this, we selected three HIV-negative
patients (confirmed HIV-negative test result on the
NHLS) for every HIV-positive patient (1:3 ratio) (Fig. 1).
The HIV-negative patients were chosen by sequentially
selecting the next three patients with a negative HIV-
test following the HIV-positive patient, by date order of
clopidogrel dispensing. Our method did not allow for
matching according to baseline characteristics. We ex-
tracted the following CAD variables from their medical
records on the ECM system: comorbidities (hyperten-
sion, dyslipidaemia, diabetes mellitus), family history of
CAD, social risk factors (tobacco-smoking, body mass
index > 25 kg/m2, ethanol-misuse), the type of ACS
(STEMI, NSTEMI and UA), the culprit coronary artery,
the region of myocardium involved, single- or multi-
vessel coronary artery disease, echocardiographic find-
ings, pharmacological and interventional management of
the patients, as well as their serum creatinine concentra-
tion on presentation. We identified medical comorbidi-
ties using discharge summary diagnoses, prescription
data and medical records on the ECM. In the public sec-
tor, hypertension, diabetes mellitus and dyslipidaemia
are diagnosed and managed according to the Adult Hos-
pital Level Standard Treatment Guidelines and Essential
Medicines List [15]. Diagnosis of hypertension requires
at least 3 blood pressure readings ≥140/90 at least 2 days
apart. Diagnosis of diabetes mellitus is made based on
the following: symptoms of hyperglycaemia or metabolic
Fig. 1 Diagram of the selection of patients for study inclusion
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decompensation with any one single test that confirms a
random plasma glucose ≥11.1 mmol/L, fasting plasma
glucose ≥7.0 mmol/L, HbA1c ≥ 6.5% or 2-h post-load
glucose ≥11.1 mmol/L. Dyslipidaemia is diagnosed based
on the finding of abnormal serum lipid levels, and treat-
ment thereof is determined by a cardiovascular risk
score (taking into account total cholesterol, high-density
lipoprotein (HDL), gender, age and smoking status) [15].
The calculation of the 12-month period prevalence of
HIV-positive patients presenting to TBH with ACS in
2018 was determined from the entire 2018 sample using
a simple proportion calculation. From this sample, a
sub-sample consisting of just those infected with HIV
(exposed) and three times the number of exposed with a
confirmed negative HIV test (unexposed) were selected
for further statistical analysis. Data were analysed using
Stata version 11.0 (StatCorp, College Station, TX, USA).
Baseline characteristics of exposed and unexposed pa-
tients were compared by chi-square tests or 2-sided
Fisher’s exact tests for categorical variables and T-tests
or Wilcoxon rank-sum tests for continuous variables.
Normally distributed data were described using means,
medians and standard deviations (SD). 95% confidence
intervals (CIs), odds ratios (ORs), and p-values were de-
rived for all appropriate data. Logistic regression was
performed, controlling for age and sex, in order to deter-
mine associations between risk factor profile/cardiac
manifestations in those presenting with ACS and HIV-
status. Adjusted 95% CIs, ORs and p-values were derived
after such adjustment. Statistical significance was set at a
p-value of less than 0.05.
Ethical approval for the study as well as a waiver of
consent was obtained from the Human Research Ethics
Committee of the Faculty of Medicine and Health
Sciences of Stellenbosch University (Reference number:
U19/05/023).
Results
Prevalence of HIV in ACS
We identified 889 patients who presented to TBH in
2018 with the diagnosis of ACS of which 30 patients
were HIV-positive to give a 12month period prevalence
of 3.4% (95% CI 2.3–4.8) (Fig. 1).
Baseline characteristics
Thirty HIV-positive ACS patients were compared with
90 randomly selected HIV-negative ACS patients, with
the following findings (Table 1): The HIV-positive
patients were on average 7 years younger (50 years com-
pared with 57 years), more frequently men (n = 20/30;
67% compared with n = 50/90; 56%), had a lower preva-
lence of medical comorbidities (hypertension, dyslipidae-
mia and diabetes mellitus) (n = 20/30; 67% compared
with n = 83/90; 92%), and a lower prevalence of a family
history of CAD (n = 2/30; 7% compared with n = 18/90;
20%), even after adjusting for age and sex. There was no
Table 1 Characteristics of HIV-positive compared to HIV-negative patients (crude and adjusted)






Age (years), mean (SD) 50 (11.90) 57.32 (11.63) 0.95 (0.91–0.98) 0.008#
Male 20 (66.7%) 50 (55.6%) 1.60 (0.67–3.80) 0.586#
Cardiovascular risk factors
Medical comorbidities 20 (66.7%) 83 (92.2%) 0.17 (0.06–0.50) 0.21 (0.07–0.65) 0.007
Hypertension 13 (43.3%) 64 (71.1%) 0.31 (0.13–0.73) 0.39 (0.16–0.97) 0.044
Dyslipidaemia 7 (23.3%) 45 (50.0%) 0.30 (0.12–0.78) 0.28 (0.11–0.76) 0.012
Diabetes mellitus 4 (13.3%) 34 (37.8%) 0.25 (0.08–0.79) 0.31 (0.10–1.00) 0.051
Personal history CAD 4 (13.3%) 27 (30.0%) 0.36 (0.11–1.13) 0.48 (0.15–1.60) 0.234
Personal history CVA 3 (10.0%) 10 (11.1%) 0.89 (0.23–3.47) 0.70 (0.17–2.93) 0.630
PVD 3 (10.0%) 10 (11.1%) 0.89 (0.23–3.47) 1.08 (0.26–4.51) 0.913
Family history CAD 2 (6.7%) 18 (20.0%) 0.29 (0.06–1.31) 0.20 (0.04–0.99) 0.048
Social risk factors 25 (83.3%) 74 (82.2%) 1.08 (0.36–3.25) 0.42 (0.11–1.55) 0.192
Smoking 23 (76.7%) 67 (74.4%) 1.13 (0.43–2.97) 0.57 (0.18–1.76) 0.329
BMI > 25 kg/m2 7 (23.3%) 29 (32.2%) 0.64 (0.25–1.66) 0.56 (0.21–1.50) 0.249
Ethanol-misuse 3 (10.0%) 10 (11.1%) 0.89 (0.23–3.47) 0.60 (0.14–2.45) 0.472
Serum creatinine (μmol/L), median (IQR) 71.5 (59–98) 82.5 (66–103) 0.99 (0.97–1.00) 0.99 (0.98–1.01) 0.361
OR odds ratio, CI confidence interval, SD standard deviation, CAD coronary artery disease, CVA cerebrovascular accident, PVD peripheral vascular disease, BMI body
mass index, IQR inter-quartile range
aadjusted odds ratio conditioned on age and sex. #crude p-value. Bolded text = statistically significant
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difference in the social risk factor profile of the patients
between the two groups. Although statistically nonsignif-
icant, mention is made of the 11 μmol/L higher median
serum creatinine in the HIV-negative sub-group.
Acute coronary syndrome information
Twenty-three (n = 23/30; 76.6%) HIV-positive patients
presented with a STEMI compared to 48 (n = 48/90;
53.3%) controls, with HIV-positive patients having 3.12
greater odds (95% CI 1.2–8.4) of presenting with a
STEMI after adjusting for age and sex (Table 2). Fur-
thermore, HIV-positive patients had 3.03 greater odds
(95% CI 1.2–8.0) of having single-vessel disease after
adjusting as above (n = 16/30; 53% compared with n =
19/90; 21%). Although statistically nonsignificant, men-
tion can be made of the increased prevalence of left an-
terior descending (LAD) artery involvement in the HIV-
positive group (n = 16/30; 53.3%) compared to the HIV-
negative group (n = 38/90; 42.2%), translating into more
LAD-territory infarcts in the former (Table 3).
Echocardiographic information
There was no difference in the echocardiographic data
between the two groups, with the exception of the left
ventricular internal dimension at end-systole (LVIDs),
which was statistically significantly smaller in the HIV-
positive compared to the HIV-negative sub-group (3.37
mm compared with 3.96 mm) (Table 4). The systolic
function was equally impaired in both groups.
HIV-specific information
The median CD4+ count in those with available CD4+
results in the HIV-positive sub-group was 271 cells/mm3
(Table 5). Twenty-two patients (n = 22/27; 81.5%) had a
CD4+ count <500cells/mm3, with a nadir CD4+ count of
41 cells/mm3. Seventeen (n = 17/26; 65.4%) patients were
virally suppressed (HIV VL < 200 copies/mL) and 13
(n = 13/26; 50%) had viral loads lower than detectable
limits (HIV VL < 20 copies/mL). The majority of the
HIV-positive patients were on ART at the time of the
ACS event (n = 20/30; 66.7%), while eight (n = 8/30;
26.7%) were ART-naïve and two (n = 2/30; 6.7%) had
defaulted their medication at the time of the event. Of
the HIV-positive patients receiving ART, 15 (n = 15/20;
75%) were on a non-nucleoside reverse transcriptase in-
hibitor (NNRTI) – based regimen and five (n = 5/20;
25%) were on a protease inhibitor (PI) – based regimen.
Management
There was no difference in the immediate or long-term
management of the patients (Table 3). Rates of thromb-
olysis in patients with STEMIs did not differ significantly
between HIV-positive and HIV-negative patients.
Discussion
In this retrospective cross-sectional analysis of patient
records at a large tertiary hospital in Cape Town,
South Africa, the 12-month period prevalence of HIV
in those hospitalised with ACS was 3.4% (95% CI 2.3–
4.8). HIV-positive patients were younger, predomin-
antly male, had a lower prevalence of medical comor-
bidities and a lower prevalence of a family history of
CAD, even after adjusting for age and sex. HIV-
positive patients experienced more STEMIs and single-
vessel disease. Our findings contribute data on the
prevalence and presentation of HIV in ACS from
South Africa with the largest ART program in the
world and a rising rate of non-communicable disease-
attributed morbidity and mortality [16].
The relative absence of traditional risk factors in the
HIV-positive sub-group suggests additional pathogenic
mechanisms in these patients; one being the higher
rates of sub-clinical dyslipidaemia seen in HIV-positive
individuals. HIV autopsy studies have shown evidence
of premature CAD in HIV-positive patients even before
initiation of ART, as a result of complex dyslipidaemic
patterns: reduced total serum cholesterol, reduced
high-density lipoprotein (HDL), reduced apolipoprotein
B, and increased low-density lipoprotein (LDL) [4].
Despite a lower prevalence of diagnosed dyslipidaemia
in our HIV-positive sub-group, we do not have data on
their lipid profiles at the time of presentation for ACS,
Table 2 ACS presentation of HIV-positive compared to HIV-negative patients (crude and adjusted)
Outcome, n (%) HIV+ (n = 30) HIV- (n = 90) Crude OR (95% CI) aaOR (95% CI) Adjusted p-value
ACS type
STEMI 23 (76.7%) 48 (53.3%) 2.88 (1.12–7.37) 3.12 (1.16–8.40) 0.024
NSTEMI (reference) 7 (23.3%) 32 (35.6%)
UA (reference) 0 (0.00) 10 (8.3%)
Single/multi-vessel disease
Single-vessel 16 (53.3%) 19 (21.1%) 4.27 (1.78–10.27) 3.03 (1.16–7.96) 0.024
Multi-vessel (reference) 14 (46.7%) 71 (78.9%)
aadjusted odds ratio conditioned on age and sex. Bolded text = statistically significant. OR odds ratio, CI confidence interval, ACS acute coronary syndrome, STEMI
ST-elevation myocardial infarction, NSTEMI non-ST-elevation myocardial infarction, UA unstable angina
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which may have revealed a higher prevalence of sub-
clinical dyslipidaemia. We did not find an association
between HIV-positive patients suffering from ACS and
those receiving PIs which makes it plausible that there
is another risk factor apart from PIs in the causation of
dyslipidaemia and ACS. Our sample size is however
limited to draw definitive conclusions. The cardiovascu-
lar protective effect of ART however is supported by
early ART-initiation to prevent CAD in HIV-positive
individuals, as well as the increased risk of CAD and
other comorbidities associated with ART-interruption
[17]. Therefore, it is plausible that it is the combined
effect of HIV infection and certain ART drugs that re-
sults in complex sub-clinical dyslipidaemic patterns in
HIV-positive patients, thereby increasing their risk for
CAD and resultant ACS.
Table 3 Angiographic data and management of HIV-positive compared to HIV-negative patients
Outcome, n (%) HIV+ (n = 30) HIV- (n = 90) p-value
Culprit coronary artery
Left main stem 0 (0.0%) 2 (2.2%) 1
Left anterior descending 16 (53.3%) 38 (42.2%) 0.299
Diagonal (1st branch) 1 (3.3%) 5 (5.6%) 1.000
Circumflex 4 (13.3%) 8 (8.9%) 0.492
Oblique marginal (1st branch) 1 (3.3%) 3 (3.3%) 1.000
Right coronary artery 6 (20.0%) 25 (27.8%) 0.476
Other 1 (3.3%) 1 (1.1%) 0.439
Region affected by STEMI
Antero-septal 13 (56.5%) 26 (54.2%) 1
Lateral 9 (39.1%) 11 (22.9%) 0.171
High-lateral 1 (4.4%) 4 (8.3%) 1
Inferior 9 (39.1%) 22 (45.8%) 0.620
Posterior 2 (8.7%) 8 (16.7%) 0.482
Right ventricle 1 (4.4%) 2 (4.2%) 1
Other 0 (0.0%) 1 (2.1%) 1
Radiological investigations
Echocardiogram 22 (73.3%) 77 (85.6%) 0.165
MRI 1 (3.3%) 6 (6.7%) 0.670
Intervention in those with STEMI
Thrombolysis 17 (73.9%) 30 (62.5%) 0.341
PCI 16 (69.6%) 38 (79.2%) 0.375
Conservative 2 (8.7%) 5 (10.4) 0.820
Discharge medication
Antiplatelet 30 (100.0%) 90 (100.0%) 1
Angiotensin converting enzyme-inhibitor 26 (86.7%) 79 (87.8%) 1
Angiotensin receptor blocker 1 (3.3%) 7 (7.8%) 0.678
Beta-blocker 30 (100.0%) 86 (95.6%) 0.571
Statin 28 (93.3%) 90 (100.0%) 0.061
Simvastatin 25 (92.6%) 88 (97.8%) 0.227
Atorvastatin 2 (7.4%) 2 (2.2%) 0.227
Nitrate 2 (6.7%) 9 (10.0%) 0.729
Calcium-channel blocker 0 (0.0%) 6 (6.7%) 0.335
Thiazide diuretic 0 (0.0%) 7 (7.8%) 0.190
Loop diuretic 5 (16.7%) 17 (18.9%) 1
Potassium-sparing diuretic 1 (3.3%) 1 (1.1%) 0.439
STEMI ST-elevation myocardial infarction, MRI magnetic resonance imaging, PCI percutaneous coronary intervention
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An additional suggested pathogenic mechanism for
CAD in HIV-positive individuals is immune-system dys-
function, which can be directly measured by the number
of CD4+ lymphocytes in the body. Lichtenstein et al.
showed that a CD4+ count of less than 500 cells/mm3 is
an independent risk factor for CAD, with comparative
attributable risk of approximately 20% - a figure similar
to several other traditional CAD risk factors [18]. The
majority (81%) of patients in our study had CD4+ counts
less than 500cells/mm3 which suggests an increased risk
of CAD in these patients. Current detectable viraemia
has been found to be a further risk factor for CAD, due
to its contribution to an environment of persistent
chronic inflammation [17]. Even virally suppressed HIV-
positive patients have higher levels of inflammatory
markers than those without HIV; thereby predisposing
them to CAD [8].
The predominant presentation of single-vessel CAD
and STEMIs in the HIV-positive patients in our study
(even after adjusting for age and sex) is most likely due
to the unique histological characteristics of coronary
plaques in these patients. Virtual histology intravascular
ultrasound analysis of HIV-positive patients affected by
ACS has shown a high prevalence of unstable plaque
morphology that is rich in necrotic tissue, less calcific,
and has a thicker fibrous cap compared to that seen in
traditional CAD [4]. Non-calcified plaques are more
likely to rupture than calcific or mixed plaques, putting
these patients at higher risk of single-vessel STEMI than
their HIV-negative counterparts [19]. This higher plaque
vulnerability is thought to be linked to the chronic in-
flammatory process of being infected with the HI virus
itself. Furthermore, Moran et al. found that HIV-positive
patients with single-vessel disease had higher Gensini
Scores [20] than HIV-negative controls with single-
vessel disease, indicating more severe vessel stenosis in
the former [19]. The presence of more extensive, more
vulnerable non-calcific, fibro-fatty plaque could also ex-
plain the higher prevalence and earlier onset of ACS in
the HIV-positive population.
The mild systolic dysfunction seen in both groups is in
keeping with the echocardiographic changes expected
after a myocardial infarction. We would expect more ad-
vanced diastolic dysfunction in our HIV-negative sub-
group as a result of the increased prevalence of hyper-
tension in this group. A study done in Cameroon com-
paring the left atrial remodelling in hypertensives
compared to healthy patients showed the hypertensive
patients to have a larger left atrial diameter, surface area
and volume, indicating an altered diastolic function in
these patients [21]. Although statistically nonsignificant,
it is plausible that the 11 μmol/L higher mean serum
creatinine in the HIV-negative sub-group can be ex-
plained by the increased prevalence of medical comor-
bidities in this group, resulting in a higher incidence of
target-organ damage which may manifest as sub-
clinical/clinical chronic kidney disease. Serum creatinine
is reported in many studies as a prognostic marker for
overall cardiac mortality. In a study by Matts et al. it was
found that each nine μmol/L (0.1 mg/dL) rise in baseline
serum creatinine had a 36% increased relative risk of fu-
ture overall mortality and a 47% increased relative risk
Table 4 Echocardiographic parameters of HIV-positive compared to HIV-negative patients
Variable, mean (SD) except where specified HIV+ HIV- p-value
LA diameter (mm) (n = 48) 3.47 (0.52) 3.84 (0.67) 0.124
LA area (cm2) (n = 73) 17.89 (4.28) 19.58 (4.80) 0.219
LVIDs (mm) (n = 73) 3.37 (0.54) 3.96 (0.90) 0.019
LVIDd (mm) (n = 77) 4.72 (0.49) 5.11 (0.83) 0.083
Ejection fraction (%) (n = 86) 45.4% (11.56) 44.3% (12.46) 0.758
E/e’ (n = 69) 12.18 (5.06) 14.06 (8.22) 0.4171
Effusion: n (%) (n = 77) 2 (13.3%) 7 (11.3%) 1
Bolded text = statistically significant. SD standard deviation, LA left atrium, LVIDs left ventricular internal diameter end-systole, LVIDd left ventricular internal
dimension end-diastole, E/e’ ratio between early mitral inflow velocity and mitral annular early diastolic velocity
Table 5 Immunological and ART status of HIV-positive patients
Variable, n (%) except where specified HIV+
Viral load (copies/mL) (n = 26)
Suppressed (< 200) 17 (65.4%)
Unsuppressed (> 200) 9 (34.6%)
CD4+ count (cells/mm3) (n = 27)
Median (IQR) 271 (355)
ART status (n = 30)
Treated with ART at time of event 20 (66.7%)
ART-naïve 8 (26.7%)
Defaulted ARTs 2 (6.7%)





IQR inter-quartile range, ART anti-retroviral therapy
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for future atherosclerotic CAD mortality (no confound-
ing factors present) [22]. This potentially translates into
a 44% increased relative risk of overall future mortality
and a 57% increased relative risk for future atheroscler-
otic CAD mortality in the HIV-negative patients in our
study. Such a finding in our study cannot be over-
interpreted due to our small sample size.
As there is no current evidence for a change in imme-
diate or long-term management of CAD and ACS based
on HIV status, all patients in our study were treated
similarly. Simvastatin coadministered with PIs are ex-
pected in increase simvastatin concentrations markedly
due to CYP3A inhibition [23]. However, we noted that
80% of patients on PIs incorrectly received simvastatin.
The more frequent prescription of calcium-channel
blockers and thiazide diuretics in the HIV-negative sub-
group is most likely as a result of the increased preva-
lence of hypertension in this population.
Overall, our findings were consistent with the litera-
ture. There is limited global data on the prevalence of
HIV in people presenting with ACS, but our findings are
similar to the 2.4% HIV prevalence found in the CAD
sub-group (consisting of 581 patients) of all de novo
cases of heart disease presenting to a tertiary hospital in
Soweto, South Africa [24]. These values are significantly
lower than both the 13.1% estimated national HIV-
prevalence in South Africa in 2018 and the 7% preva-
lence of HIV in a population of people with ACS in a
HIC such as Spain [11]. This may be due to the under-
reporting of HIV in ACS in South Africa as evidenced
by the large portion of untested patients in our study
(Fig. 1) [1]. Furthermore, it may be due to other con-
founding factors; one being age: HIV-prevalence is high-
est in young adults whereas ACS primarily affects the
elderly. Despite this, data from a study conducted in
Québec, Eastern Canada, showed the incidence of ACS
to be 3.88 in the HIV-positive cohort compared to 2.21
in the HIV-negative cohort per 1000 patient-years, irre-
spective of exposure to ART [25]. A study conducted in
Boston, Massachusetts, showed increased ACS rates per
1000 person-years in HIV-positive vs HIV-negative pa-
tients (11.13 vs 6.98), even after adjusting for age, sex,
race, hypertension, diabetes and dyslipidaemia [12]. The
demographic profile and CAD risk factor profile of the
patients in our study was consistent with that seen in
the literature. Furthermore, the type of ACS and number
of involved coronary arteries of the HIV-positive patients
in our study matched that seen in the literature. Various
studies from the USA and France showed angiographic
findings of fewer involved vessels and a greater burden
of inflammatory plaque in the HIV-positive cases as
compared to the HIV-uninfected cases [7]. Our findings
of a predilection for LAD artery involvement in the
HIV-positive patients are supported by those of Vachiat
et al. who showed the LAD to be the most common cul-
prit artery (60%) in HIV-positive patients with ACS [26].
The same proportion of HIV-positive and HIV-
negative patients in our study underwent percutan-
eous coronary intervention (PCI), but we have no
follow-up data on long-term success rates of such an
intervention. A Spanish study showed a lower long-
term success-rate in HIV-positive patients who under-
went PCI compared to HIV-negative patients (75%
versus 85% success-rate respectively) [27].
An interesting finding from our study was that despite
a nonsignificant increased unadjusted prevalence of
smoking seen in HIV-positive compared to HIV-
negative patients, this finding was reversed when adjust-
ing for age and sex. This finding could perhaps explain
the heterogeneity in smoking data when comparing
HIV-positive and HIV-negative patients with ACS. The
majority of studies show a positive correlation between
HIV-infection and smoking; however, when matching on
age and sex, Dwyer et al found no difference in rates of
smoking between HIV-positive and HIV-negative sub-
groups [1, 28].
Our study has a number of limitations. First, the retro-
spective, observational design limits its ability to control
for unmeasured confounders. Second, our sample size is
limited which did not allow us to perform sub-group
analyses. Third, we may have underestimated the HIV-
prevalence within the ACS population due to the relative
infrequent reporting of HIV-results. It is not routine for
everyone presenting to a healthcare facility in South Af-
rica to be tested for HIV, meaning that the actual preva-
lence of HIV within the ACS population might be
higher than reported in our study. Fourth, our sample is
from a single centre and may not be representative of
South Africa or sub-Saharan Africa. Last, we were con-
fronted with missing data that were not always collected
as part of routine clinical care. CD4+ counts and viral
loads were not available for all HIV-positive patients,
and when available, were not always taken during the
same admission as for the ACS event. It is also possible
that we may have missed cases with our retrospective
design. However, given that we used electronic database
systems for our case identification and data extraction,
we argue that this risk was minimised.
Conclusions
In conclusion, we found that HIV-positive patients with
ACS were younger, more likely to present with STEMIs
and single-vessel disease, and had limited traditional
ACS risk factors. This suggests additional pathogenic
mechanisms for the development of CAD and ACS in
patients with HIV; possibly attributed to the inflamma-
tion and immune-activation caused by infection with
HIV. To date, ART is the most important treatment
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intervention highlighting the importance of prompt initi-
ation of ART in patients with HIV [29]. The younger
age of ACS presentation in patients with HIV highlights
the importance of early, rigorous screening for risk fac-
tors and early diagnosis of CAD for active management.
Our prevalence finding of 3.4% of HIV in ACS may be
an under-estimate in South Africa and should be pro-
spectively studied.
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